Table 3.
Frequency and association between initial pharmacotherapy for GDM and treatment modification
| Frequency of substitution (row percentage) n (%) | Association between initial pharmacotherapy and modification | |||||
|---|---|---|---|---|---|---|
| Overall | Glyburide | Metformin | Insulin | Metformin compared to insulin | Glyburide compared to insulin | |
| Initial pharmacotherapy | Adjusted risk ratio (95% CI) | Adjusted risk ratio (95% CI) 1 | ||||
| Glyburide (N=4,984) | 402 (8.1) | -- | 82 (1.6) | 320 (6.4) | -- | 4.40 (3.44, 5.66)* |
| Metformin (N=2,147) | 423 (19.7) | 117 (5.4) | -- | 306 (14.3) | 11.67 (9.50, 14.30)* | -- |
| Insulin (N=3,276) | 67 (2.1) | 19 (0.6) | 48 (1.5) | -- | 1.00 | 1.00 |
1
Adjusted for calendar year, U.S. region, maternal age, number of dependent children, and endocrine comorbidity, and metformin use in early pregnancy.
*
p-value <0.05.
2
Treatment modification may include either addition or replacement of the prior regimen.